Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Alcon deal closes

This article was originally published in The Tan Sheet

Executive Summary

Novartis closes its acquisition of a 25 percent stake in Alcon as part of an agreement with Nestle announced in April. Nestle said previously it would sell 74 million shares of its Alcon eye-care product firm to Novartis at $143.18 a share (1"The Tan Sheet" April 14, 2008, In Brief). Novartis purchased the stake in Alcon for approximately $10.4 billion in cash - $200 million less than previously announced, to account for the "Alcon dividend paid in May 2008 for these shares to Nestle rather than Novartis," the Switzerland-based firm says. There is also an optional second step, which would allow Novartis to acquire the remaining 52 percent stake held by Nestle between January 2010 and July 2011 for a price not exceeding $28 billion. Novartis says completion of the optional second step would make Alcon a "majority-owned subsidiary of Novartis, strengthening a portfolio focused on growth areas of health care"...

You may also be interested in...

Novartis eyes representation on Alcon board

Alcon will vote on the conditional election of directors nominated by Novartis at an "extraordinary" shareholder meeting Aug. 16. Prospective directors would "face an obvious conflict of interest with respect to Novartis' merger proposal to Alcon's minority shareholders," said Thomas Plaskett, chairman of the Alcon independent director committee. Novartis acquired 25 percent of Alcon in 2008 and is in the process of buying out Nestle's remaining 52 percent stake in the eye care firm (1"The Tan Sheet" July 14, 2008, In Brief). Novartis' five board nominees would replace directors nominated by Nestle. Alcon continues to resist Novartis' bid for its remaining 23 percent stake, once again calling the bid "grossly inadequate" in a June 28 release (2"The Tan Sheet" Feb. 15, 2010)

Abbott Targets Diversity, Reels In Advanced Medical Optics For $2.8 Billion

Drug, device and nutritional maker Abbott is betting that its $2.8 billion purchase of laser vision correction, contact lens care and cataract surgery product maker Advanced Medical Optics will pay off once the economy recovers

Novartis to acquire piece of Nestle’s Alcon

Nestle will sell 74 million shares of its Alcon eye-care product firm to Novartis for $143.18 per share, the Swiss firms announce April 7. After the deal closes, Novartis will own approximately 25 percent of Alcon's outstanding shares, leaving Nestle as Alcon's majority shareholder with 52 percent of outstanding shares, Novartis says. The agreement also grants Novartis a call option to buy Nestle's remaining shares at $181 per share, according to the firms. Additionally, Nestle will have a put option to sell its remaining Alcon shares at "the lower of Novartis' call price of $181 per share" or "20.5 percent premium above the market price of Alcon shares," which will be calculated based on the average share price of Alcon during the week before the put option. Alcon's consumer products include the OPTI-FREE contact lens solution brand and Systane eye lubricating drops; the firm posted $5.6 billion in sales in 2007...


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts